Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Look at that. It is happening a day or 2 after I said the Fed could ruin things the state have set up.
I have not read the news but have heard comments from casual talk today.
ENDV is the secure investment.
Everyone wants better health!!!
You won't find the Gov't trying to block devices that will make people well/healthy.
We need to stop looking at L2. It's driving us crazy. That's why I've been trying to create other conversations based on the new stuff we have.
Doesn't seem to be working...hehe.
I've brought up things about Sofpulse...who wants to take the reins and give info and updates on the concussion study?
Speaking of We Heal Animals....look at this video. Do you think this device is infringing on our Sofpulse patent?
ENDV was in talks for many months with RGN.
There was a RGN PR back in March 2017.
This PR was about RGN trying to sell their assets and technology.
"The company has been in discussion with another party that has expressed an interest in acquiring the Company’s PEMF and TES assets and so has decided not to offer them for sale. The Company had previously expressed a desire to sell all three assets but withdrew the offer both because baseless claims were made that another entity had a prior right to buy the Company and of the pendency of an offer from a legitimate buyer to purchase all the the assets. The entity claiming to have a prior right to purchase the Company has withdrawn that claim, and the pending offer to purchase has narrowed to PEMF and TES."
I would love for your theory to be right, but I believe it will not come to reality in the near term, if at all.
I believe ENDV has been stopping the work with Cytotronics and stem cells. They still might be working on something small scale in the background but all signs point to a temporary stoppage.
Working with stem cells is a very slow and long testing process. It is most likely an expensive one at that also. I think ENDV is focusing on the revenue producing assets (RGN) and Immunotronics for now.
What happened to the PR of hiring attorneys to get the orphan drug designation? It must have failed and ENDV is keeping it swept under the rug?
What happened to the hyped GVHD testing?
I think ENDV thought Immunotronics would be faster to bring to the market and focused on that.
I would love for ENDV to pull a Cytotronics update out of their rabbit hat and say "surprise". I just don't think that will happen.
Have you noticed they don't even mention stem cell research anymore in their company summary in the latest PRs?
Endonovo only acquired some assets from RGN rather than purchasing the entire company. The original plan was to purchase the company outright. That is why there is a big monetary difference of acquisition this time around.
RGN is looking for a buyer of their other technologies. Also as Biotech mentioned, there is a penalty against RGN involved for breaking the binding letter of agreement.
We may have a difference of opinion, but that is why we have this board for open discussion.
I may have countered your theory, but I hope you are right for all of the long holders that originally bought into the Cytotronics hype.
Did a little history investigation of Sofpulse.
Aug. 1998 - ADM Tronics acquires Sofpulse assets.
April 2005 - Ivivi (a subsidiary of ADM) introduces the next generation of Sofpulse (New and improved version).
Dec. 2008 - FDA gives clearance to Ivivi for 3 models of Sofpulse.
Sep. 2009 - Ivivi sells some assets to Steve Gluckstern (CEO of Rio Grande..although RGN is not mentioned in PR). The assets are not specifically mentioned but this creates business relationship between the companies.
SEP 2015 - Rio Grande acquires Ivivi's tPEMF technology. RGN was previously licensing the use of it.
Seems ADM Tronics is doing the manufacturing and logistics of the device.
This device has been around in it's current FDA approved form since end of 2008?
Has it been a victim of mismanagement?
I can understand Ivivi's challenge of handling it during the financial crisis of 2007-2008 and then the delay of FDA approval.
What is Rio Grande's excuse for sitting on it during the years afterwards? That's a long time to sit on a FDA approved device.
Let's see if Endonovo can market a FDA approved device that is years old and never created a big buzz in the medical community.
I did see an article from Aetna (believe dated April 2017) stating they are aware of the device but it has a lack of published data on it's effectiveness.
Endonovo...are you reading this?
Learn from past mistakes.
New Form 4 is out. No missed trading days. Continuous buying by Mann.
I hope it will be like a true rocket and not like a failed North Korean missle <grin>
Hope so. MBOT is my biggest holding at the moment.
They sent out a tweet. People speculating big news coming soon
Ouch. Sorry for your loss with Ivivi. Sofpulse has returned to your portfolio once again. Hopefully it will make up for the bad past experience .... with interest.
The 2 signals work in different ways. Cannot use 1 as a blanket for all ailments.
In my opinion, if/when the heart clinical results produce FDA approval, that will be the major boost for ENDV.
The Softpulse has been out in the market for a while. It has not created a major buzz in the medical field so far. Is it looked upon as a gimmick by medical professionals? Hopefully ENDV can market it better.
Ok....hence why ENDV is now moving to the tPEMF terminology.
Hopefully they will keep the Immunotronics label for the organ studies. I see they did leave out the Immunotronics term in their latest PRs in the About Endonovo section.
It has become a little confusing with the various TVEMF, PEMF, and tPEMF.
As can be seen from the section of About Endonovo on their new PRs....
"The Company's non-invasive electroceuticals use targeted-Pulsed Electromagnetic Fields (tPEMF) to induce micro-currents in tissues to target proinflammatory, fibrogenic and regenerative signaling pathways for the treatment of cardiovascular and cerebrovascular diseases, as well as for the treatment of chronic kidney and liver disease. "
tPEMF appears to be their new acronym to cover all testing (using TVEMF and/or PEMF)
The TVEMF is their patented square wave signal to be used on the organ clinicals and the PEMF signal is what is used with the Softpulse and Theracap devices.
ENDV should see revenue immediately from Softpulse. It is already on the market. We just don't know how the marketing was done with this device before and if Drs. are on board to recommend it to patients.
It is my understanding that the Theracap should also hit the market sometime this year. There is clinical testing in process right now.
I see there is a Sofpulse knockoff for animals called the Assissi Loop.
ENDV should reactivate We Heal Animals and market a Sofpulse equivalent for animals as well.
They have a good donaim reserved for it.
www.wehealanimals.com
You could be right.
I did some more research on Sofpulse this AM. I did not know It has been marketed for years now.
I see it was originally created by Ivivi around 2008. Ivivi was operated by the now owner of Rio Grande.
The device is now being sold and distributed by ADM Tronics Unlimited in NJ.
My original statement was based on the verbage of ENDV PR when they acquired RGN assets.
I believe we need to wait until ENDV is registered with the FDA as the new owner of this technology.
Bitcoin could potentially be a bubble waiting to burst.
Marijuana is interesting but could the US Federal Gov't one day try to put the brakes on what the states are passing?
ENDV, on the other hand, is working on making people healthy. What is there not to like with that?
Low risk. High reward.
Our CEO (in 2016) has said "only 10 percent of drugs entering Phase I trials actually make it to market translating into large financial losses for the pharmaceutical industry."
".....over 40 percent of marketing candidate drugs being terminated as a result of unexpected toxic effects, particularly in the liver."
Yet those drug companies have share prices higher than ENDV.
(shaking my head).
And we are working on a technology to help repair damaged livers.
Wake up BIO investors.
Are you too distracted with fancy gifts and toys from the Pharma companies?
This will help explain what you are seeing.
https://www.google.com/amp/s/incrediblepennystocks.wordpress.com/2013/06/25/incredible-penny-stocks-what-is-a-form-t-trade/amp/
"Unlike pharmaceutical-based treatments, the blood-brain-barrier cannot hinder the delivery of the Company's tPEMF therapy to the brain parenchyma, which is one of the major hurdles to the effective treatment of CNS disorders."
We have a technology that works potentially better than pharmaceutical pills, less risk of side effects, a technology that can be utilized on VARIOUS ailments, and we cannot even stay above $.07???
What the hell is going on here?
How can ENDV share price lag so far behind any pharmaceutical company that focuses only on 1 drug and will take years to go through 3 phases of testing?
Is it due to being on OTC?
Yes, I know ENDV has more O/S, but if you equate the O/S and share price equivalent to other Pharmas, we should be higher.
Maybe ENDV needs investment assistance from a BIG name company/person to show confidence in the technology.
Maybe Mann is trying his hardest to keep it low to accumulate as much as he can.
I see it on NITE now on my L2
Happy New Year Endonovo.
Hope you made a New Years Resolution to communicate more often with the shareholders in 2018.
You certainly have a lot more potential news worthy events this year.
Just like the Power Cube from years ago also.
One could make the argument that those products were marketed under the former business partners.
We have to give Alex time to righten the ship.
Start looking at things with fresh eyes from the time Alex has been managing the company without the former associates.
I vote for Bush Gardens.
It's in Tampa, where UATG is located.
It's only 1 hr away from Orlando for those that still want to visit one of those parks.
Well, on a good note, BMIC did stay away today. We had other forces against us.
Looking forward to a fresh start in the new year!!
That is no dilution of the "new" note.
They have dilution from older note happening now. It is how they can operate without any revenue.
Now is when I received notice that ENDV is doing an offering.
Explains the drop.
I don't think was Mgmnt. BMIC is not in play.
648k volume in first 15 min of trading and there is no news.
Think we just lost an impatient investor.
BMIC needs to go on a vacation! <grin>
I believe you see the ad on FB because FB sees you have visited their FB page and/or visited their website.
I don't believe FB is showing it to all people.
Hopefully if someone searched for socks it causes a link and they would see it also.
Anyone else notice the Cytotronics platform seems to have been eliminated from the "about Endonovo" section of the new PRs?
There is no specific mention of cells anymore. It's all focused on Immunotronics and the new technology.
What happened to GVHD treatment?
Toxicology testing?
Any of the stem cell testing and patents that was PRd years ago?
I know the new PRs are about the RGN assets and testing from those assets but the "about" section is for providing general info about the company.
You and Pycho competing to be top shareholder.
With the Form 4 that was released today, Fri. 22nd has no purchases and the PR was released on Mon. 26th.
The 26th though, had a lot of purchases. Maybe to make up for the missed Friday?
Now I have seen 2 incidents of a non purchase day, both times 1-2 days within a significant PR.
BUT we will not see that clue in advance as the Form 4 is released after both scenarios.
I suppose someone really paying attention to the time and sales might pick up on it.
I think only way to get true SEC involvement is to have proof of actual communication between MMs (phone calls and/or emails).
The big mystery is which news is it going to take to make this blow up hard.
Unfortunately this PR is not anything really new (with ENDV specifics). We had already previously read most of this information. It is not even creating a volume spike.
Looks like the FDA trial for the heart will not start as early as we had hoped. They are still working with the pre-clinical data. When they say early Q1 for data release we need to add more time to that, as we have seen, their timelines are never on time.
BMIC is on the front lines of the Ask.
That thing was promoted by UATG in 2014 and 2015. Seems they dropped it when it failed to gain attention in a Kickstarter type of campaign.